ERBB2 and breast carcinoma: In two breast cancer metastasis models, an LPA1/3 antagonist had no effect on primary tumor growth but significantly prevented the lung and/or liver metastasis of “triple negative” (estrogen and progesterone receptors, ER and PR, negative; HER2 normal) breast cancer.